Push to dispel myths about long-lasting contraception

Guardian Australia, Tuesday 26 September 2017 

Misplaced concerns and myths about long-acting reversible contraceptives have prompted medical experts to release Australia’s first consensus statement, saying they are more reliable and effective than condoms or the pill.

Despite their safety, efficacy and widespread use internationally, the uptake of long-acting reversible contraceptives (LARCs) is low in Australia. On Tuesday the Australian Healthcare and Hospitals Association released a consensus statement – endorsed by 18 agencies, including SHINE SA – on the use of LARCs.

Birth control: Natural methods of contraception on the rise in Australia

ABC, 22nd July 2017

Despite the messaging around safe sex and unwanted pregnancies that dominates our discussion of sexual health, a growing number of Australians are opting to risk it. A recent study out of Monash University suggests the use of so-called natural contraception methods, like withdrawal and fertility awareness, are making a comeback.

Sara Holton, a research fellow at Monash and co-author of the study, says the finding is unexpected.

New kind of male contraceptive faces biggest hurdle: drugmakers

The Age,  Published 

Doctors are on the cusp of launching the first new male contraceptive in more than a century. But rather than a Big Pharma lab, the breakthrough is emerging from a university start-up in the heart of rural India.

Years of human trials on the injectable, sperm-zapping product are coming to an end, and researchers are preparing to submit it for regulatory approval. Results so far show it’s safe, effective and easy to use – but gaining little traction with drugmakers.

Treatment guidelines after an outbreak of azithromycin-resistant Neisseria gonorrhoeae in SA

The Lancet Infectious Diseases, 17 (2), February 2017

Abstract:

Antimicrobial resistance in Neisseria gonorrhoeae is recognised globally as a public health threat. Dual therapy with ceftriaxone and azithromycin has been introduced in Australia and elsewhere as the first-line treatment recommendation for gonorrhoea. While there have been only sporadic reports of ceftriaxone-resistant gonococci, globally there have been increasing reports of N gonorrhoeae resistance to azithromycin.1 The Australian Gonococcal Surveillance Programme2 is one of the most comprehensive N gonorrhoeae antimicrobial resistance surveillance programmes worldwide.

Position statement on Human Papillomavirus (HPV) vaccination

VAC, 2015/2017

Community members have recently been expressing interest in human papillomavirus vaccines (HPV) in online discussions. Health bodies in both the UK and Ireland have recommended that all gay and bisexual men receive the vaccine in order to reduce their risk of certain cancers.

VAC developed a position statement on this issue back in July 2015 in association with Melbourne Sexual Health Centre, which states that VAC believes the vaccines should be made available free of charge to all gay, bisexual and other MSM under the age of 26, and to all people living with HIV.

Download the position statement (PDF) at this link: PositionStatement_HPVvaccination_JULY2015

UK report gives thumbs up to generic HIV drugs used as PrEP

A sexual health clinic in London has tested drug levels in users of generic PrEP medication bought online and found the drugs are genuine and effective.

Tests found adequate levels of both emtricitabine and tenofovir (used in PrEP medication Truvada) in patients’ blood, and no sample suggesting counterfeit drugs.